Study of KCCQ Scores to Predict Heart Risks and Survival in Adults on Maintenance Dialysis

What this Trial Is About

Cardiovascular disease is the leading complication and cause of death for patients with chronic kidney disease CKD, especially those with End-Stage Renal Disease ESRD undergoing dialysis. This research aims to evaluate the Kansas City Cardiomyopathy Questionnaire KCCQ, a tool that measures patient-reported heart failure symptoms, to see if changes in KCCQ scores can predict long-term cardiovascular events and overall mortality in dialysis patients. The study seeks to build a predictive model to help improve diagnosis and treatment of heart failure in this high-risk group. This is a prospective, single-center observational study involving patients on maintenance dialysis or newly diagnosed with uremia starting dialysis. There is no change to patients treatments during the study. KCCQ assessments and relevant clinical tests will be collected at enrollment and then regularly during follow-up visits over 12 months. New uremia patients will have KCCQ scores collected at 0, 1, 2, 3, 6, 9, and 12 months, while maintenance dialysis patients will be assessed at 0, 3, 6, 9, and 12 months. Participants will complete the KCCQ questionnaire and undergo clinical evaluations at each visit. Researchers will track all-cause mortality, deaths from cardiovascular causes, and hospitalizations related to cardiovascular disease over 12 months. The study involves no interventions and aims to observe natural changes in health status. Follow-up will be at least one year to monitor outcomes and collect data for the predictive model.

An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients